

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

TITLE

Containing Emerging Epidemics: a Quantitative Comparison of Quarantine and Symptom Monitoring

AUTHORS

Corey M Peak¹, Lauren M Childs¹, Yonatan H Grad^{2,3}, Caroline O Buckee^{1*}

AFFILIATIONS

1. Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston MA 02115 USA

2. Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA 02115

3. Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115

*To whom correspondence should be addressed: cbuckee@hsph.harvard.edu

19 **ABSTRACT**

20 Strategies for containing an emerging infectious disease outbreak must be non-
21 pharmaceutical when drugs or vaccines for the pathogens do not yet exist or are
22 unavailable. The success of these non-pharmaceutical strategies will not only depend on
23 the effectiveness of quarantine or other isolation measures, but also on the epidemiological
24 characteristics of the infection. There is currently no systematic framework to assess the
25 relationship between different containment strategies and the natural history and
26 epidemiological dynamics of the pathogen, however. Here we compare the effectiveness of
27 quarantine and symptom monitoring, implemented via contact tracing, in controlling
28 epidemics using an agent-based branching model. We examine the relationship between
29 epidemic containment and the disease dynamics of symptoms and infectiousness for seven
30 case study diseases with diverse natural histories including Ebola, Influenza A, and Severe
31 Acute Respiratory Syndrome (SARS). We show that the comparative effectiveness of
32 symptom monitoring and quarantine depends critically on the natural history of the
33 infectious disease, its inherent transmissibility, and the intervention feasibility in the
34 particular healthcare setting. The benefit of quarantine over symptom monitoring is
35 generally maximized for fast-course diseases, but we show the conditions under which
36 symptom monitoring alone can control certain outbreaks. This quantitative framework can
37 guide policy-makers on how best to use non-pharmaceutical interventions to contain
38 emerging outbreaks and prioritize research during an outbreak of a novel pathogen.
39

40 **SIGNIFICANCE**

41

42 Quarantine and symptom monitoring of contacts with suspected exposure to an infectious

43 disease are key interventions for the control of emerging epidemics; however, there does

44 not yet exist a quantitative framework for comparing the control performance of each.

45 Here, we use a mathematical model of seven case study diseases to show how the choice of

46 intervention is influenced by the natural history of the infectious disease, its inherent

47 transmissibility, and the intervention feasibility in the particular healthcare setting. We use

48 this information to identify the most important characteristics of the disease and setting

49 that need to be characterized for an emerging pathogen in order to make an informed

50 decision between quarantine and symptom monitoring.

51 INTRODUCTION

52 The global burden of emerging infectious diseases is growing and prompts the need
53 for effective containment policies¹⁻³. In many cases, strategies must be non-
54 pharmaceutical, as targeted drugs or vaccines for the pathogens are unavailable. Among
55 the various containment strategies, isolation of ill and potentially infectious patients is one
56 of the most intuitive, and relies on targeting individuals by tracing the contacts of known
57 cases. Contacts with symptoms can then be hospitalized or isolated, but policy makers must
58 also decide how best to handle contacts who do not meet the case definition for infection.
59 Two strategies have historically been used in the case of a potentially infected but
60 symptom-free contact: quarantine and symptom monitoring.

61 Quarantine of potentially infected contacts is a highly conservative approach to
62 epidemic containment. However, there are substantial costs associated with quarantine
63 policies, ranging from direct costs, like implementation expenses and the restriction of
64 personal liberties, to indirect costs, including stigmatization of health workers and
65 sometimes interruption of financial and trade markets⁴⁻⁸. A less conservative but
66 substantially cheaper and more socially palatable approach is active symptom monitoring
67 of contacts. In this strategy, health workers check on contacts one or two times a day,
68 moving the contacts to isolation if symptoms occur (see definitions in *Methods*). Given the
69 importance of rapid decision making in the event of novel emerging pathogens such as
70 Ebola, and the potentially devastating consequences of poor containment strategies,
71 quantitative guidelines are urgently needed.

72 The recent Ebola epidemic in West Africa highlights the uncertainties surrounding
73 the relationship between non-pharmaceutical interventions and both disease biological

74 dynamics and the intervention setting ⁷. Recommendations by the United States Centers for
75 Disease Control and Prevention (CDC) implicitly recognized the importance of the
76 implementation setting by differentiating its international response, where quarantine was
77 prioritized ⁹, and its domestic response, where symptom monitoring was prioritized ^{10,11}.
78 During the Severe Acute Respiratory (SARS) epidemic, broad quarantine interventions
79 were applied in Taiwan and subsequently abandoned ¹². These recent epidemics exemplify
80 the urgent need for evidence-based guidelines on how to decide whether quarantine of an
81 infectious disease is, according to Gates et al, at worst "counterproductive" or at best "one
82 of the few tactics that can reduce its spread" ¹³.

83 The success of these approaches is not simply a reflection of the efficiency of their
84 implementation, however, but crucially depend on the biology and natural history of the
85 pathogen in question. Disease stages are typically divided into those describing the
86 symptom history of the individual (e.g., the incubation period and duration of symptoms)
87 and the temporality of that individual's infectiousness to others (e.g., the latent period and
88 duration of infectiousness). Studies of epidemic dynamics typically focus solely on the
89 latter, but the interaction between the two has important consequences for how diseases
90 spread and the impact of interventions such as ring vaccination ¹⁴, travel screening ¹⁵, and
91 symptom monitoring. To examine the relationship between epidemiological dynamics of a
92 pathogen and non-pharmaceutical containment strategies, we develop an agent-based
93 branching model that accommodates dynamics of symptoms and infectiousness and allows
94 interventions to be targeted via contact tracing. To assess diseases with a wide range of
95 natural histories that have the potential for causing sudden, severe epidemics, we consider
96 case studies of seven known pathogens: Ebola; hepatitis A; influenza A; Middle East

97 Respiratory Syndrome (MERS); pertussis; SARS; and smallpox. We identify which disease
98 characteristics and intervention attributes are most critical in deciding between quarantine
99 and symptom monitoring, and provide a clear, general framework for understanding the
100 consequences of isolation policies during an epidemic of known or novel pathogens.

101 RESULTS

102 Intervention Effectiveness Depends on Disease Epidemiological Dynamics.

103 To assess the impact of quarantine and symptom monitoring, we developed a
104 general mathematical model of disease transmission and interventions targeted via contact
105 tracing (**Fig 1**). The model structure accommodates five key metrics of intervention
106 performance in a given setting (**Table 1**). We used particle filtering to parameterize seven
107 case studies of outbreak-prone pathogens (see *Methods* and **Table S1**).

108 **Fig 2** illustrates model dynamics for two infections with different epidemiological
109 characteristics, Ebola and influenza A, showing the range of epidemic outcomes resulting
110 from different interventions for a given R_0 value. Unimpeded exponential epidemic growth
111 in our branching model (red) can be reduced by the increasingly conservative
112 interventions of health-seeking behavior (teal), symptom monitoring (gold), and
113 quarantine (blue) (**Figs 2A-B**). Under a given intervention policy, we estimate the effective
114 reproductive number (R_e) as the average number of infections generated by an infectious
115 individual in the population. The effective reproductive number under symptom
116 monitoring (R_S), quarantine (R_Q), and the absolute difference between the two ($R_S - R_Q$)
117 increases with R_0 and differs by disease (**Figs 2C-D**).

118 We find the effectiveness of symptom monitoring and quarantine in controlling a
119 disease in a particular setting depends critically on its biological dynamics (e.g. latent and
120 infectious periods) and transmissibility (R_0) (**Fig 3a**). Holding transmissibility constant (R_0
121 arbitrarily set to 2.75 ± 0.25), biological dynamics alone strongly influence the effectiveness
122 of quarantine and especially symptom monitoring, as seen by the wide spread in R_S (**Fig**
123 **3b**).

124 In simulations with high intervention performance settings (i.e., 90% isolation
125 effectiveness, 90% of contacts traced within one day, and symptoms monitored daily),
126 diseases such as MERS and Ebola could be controlled (i.e., $R_e < 1$) with either quarantine or
127 symptom monitoring; diseases such as hepatitis A with only quarantine; but diseases such
128 as pertussis require additional interventions in order to reduce the effective reproductive
129 number below one, due in large part to pre-symptomatic infectiousness (**Fig 3c**). The
130 absolute comparative effectiveness ($R_S - R_Q$) varies widely by disease, as demonstrated by
131 the line length in **Fig 3c**. The relative comparative effectiveness ($\frac{R_S - R_Q}{R_S}$) also varies widely,
132 with quarantine reducing R_S by over 65% for influenza A and hepatitis A and by less than
133 10% for pertussis (**Fig S1**). The reader can explore results from landscapes with different
134 intervention performance settings and disease transmissibility in the **interactive**
135 **supplement** (<https://coreypeak.shinyapps.io/InteractiveQuarantine>).

136

137 **Categorizing Disease Control Frontiers**

138 In order to compare the effectiveness of symptom monitoring and quarantine, one
139 must select an appropriate metric to compare R_S and R_Q . We therefore categorized
140 intervention response heterogeneity into four control quadrants (**Fig 3a**). In quadrant I,
141 where neither intervention is sufficient to prevent epidemic growth, the relative difference
142 $\frac{R_S - R_Q}{R_S}$ can distinguish whether quarantine is merited or could be paired with other
143 strategies to achieve control. Because quarantine is by definition the more conservative
144 intervention, simulation results in quadrant II occur only stochastically. In quadrant III,
145 where both interventions are sufficient and the number of prevented cases can be more

146 directly estimated, the distinguishing metric was the absolute difference $R_S - R_Q$ and its
147 inverse ($\frac{1}{R_S - R_Q}$), which can be interpreted as the number of contacts that must be
148 quarantined in order to prevent one additional case over symptom monitoring (an analog
149 of “number needed to treat”). For the example of SARS, Day et al. propose that mass
150 quarantine may be unnecessary because effective symptomatic isolation alone would
151 sufficiently control the disease (hence placing the disease in quadrant III) ⁸. In quadrant IV,
152 where quarantine but not symptom monitoring can control the disease, quarantine would
153 be strongly considered as the minimum sufficient strategy to prevent exponential epidemic
154 growth.

155 The following two sections aim to identify which disease characteristics and
156 intervention performance metrics most strongly influence these differences in response to
157 quarantine and symptom monitoring.

158

159 **Ranking of epidemiological characteristics by importance for containment feasibility**

160 The comparative effectiveness of quarantine and symptom monitoring is strongly
161 influenced by differences in the infection’s natural history. We measured partial rank
162 correlation coefficients to examine which biological characteristics in particular are most
163 influential after controlling for the other characteristics (*Methods*). As demonstrated by
164 strongly negative partial rank correlation coefficients in **Fig 4**, increasing the duration of
165 infectiousness (d_{INF}) and elongating the latent period (T_{OFFSET}) reduced the differences
166 between quarantine and symptom monitoring, thereby making the interventions more
167 similar. Other factors, such as overdispersed heterogeneity of the basic reproductive
168 number (κ), did not influence the average effect of symptom monitoring and quarantine, as

169 reflected by a coefficient of nearly zero. Longer incubation periods (T_{INC}) increased the
170 preference for quarantine, as seen by the positive partial rank correlation coefficient for
171 both absolute and relative comparative effectiveness. However, the length of the incubation
172 period does not generally influence comparative cost-effectiveness because the number of
173 days in quarantine (d_Q) increases as the incubation period lengthens (**Fig S2**).

174 Frequently, the most politically and economically pressing concerns are whether
175 control (i.e. $R_e < 1$) is logistically achievable and what would be the least invasive
176 intervention to achieve control. **Fig 5** shows frontiers where control of an Ebola-like
177 disease requires increasingly invasive interventions, moving from health-seeking behavior
178 (teal), to symptom monitoring (gold), to quarantine (blue), the most invasive. **Fig 5a** shows
179 how this frontier is influenced by the inherent transmissibility (R_0) and timing of the latent
180 period relative to the incubation period (T_{OFFSET}), with all other characteristics similar to
181 Ebola. When R_0 is large and symptoms emerge long after infectiousness (e.g., $T_{\text{OFFSET}} > 0$),
182 even quarantine is insufficient to control the disease with optimal intervention
183 performance. However, we observe that when transmissibility is relatively low (e.g.,
184 $R_0 < 2.5$), control of this hypothetical disease can be achieved even if infectiousness
185 precedes symptoms by several days (**Fig 5a**) or if a substantial fraction of transmission
186 events occur before symptom onset (adapting the framework of ¹⁶) (**Fig 5b**).

187

188 **Ranking of intervention performance metrics by importance for containment** 189 **feasibility**

190 Policy makers facing an epidemic must also consider the expected performance of
191 interventions, since the effectiveness of targeted control policies will depend on their

192 feasibility within a particular healthcare system. Generally, we found the benefit of
193 quarantine over symptom monitoring increases with better intervention performance (i.e.
194 larger fraction of contacts traced (P_{CT}), better isolation effectiveness (γ), and shorter delays
195 in tracing a contact (D_{CT}) (**Fig 4**). However, the effectiveness of symptom monitoring
196 approached that of quarantine when the delay between symptom onset and isolation (D_{SM})
197 is shortened, due either to more frequent symptom monitoring or more sensitive detection
198 of symptoms followed by prompt isolation.

199 While these patterns were highly consistent across the case study diseases, some
200 intervention performance metrics were particularly influential in the presence of certain
201 disease characteristics. For example, diseases with short incubation periods (T_{INC}) such as
202 influenza A were strongly influenced by delays in tracing a contact (D_{CT}) (**Fig S2**).

203

204

205 **DISCUSSION**

206 A key strategy to controlling the spread of infectious diseases focuses on tracing the
207 contacts of infected individuals, with the goal of limiting subsequent spread should those
208 contacts become infected and infectious. Here we present the first study comparing the
209 effectiveness of the two primary non-pharmaceutical interventions: symptom monitoring
210 and quarantine. We show that the interventions are not equivalent and that the choice of
211 which intervention to implement to achieve optimal control depends on the natural history
212 of the infectious disease, its inherent transmissibility, and the intervention feasibility in the
213 particular healthcare setting.

214 Our results show that the benefit of quarantine over symptom monitoring is
215 maximized for fast-course diseases (short duration of infectiousness and a short latent
216 period compared to the incubation period), and in settings where isolation is highly
217 effective, a large fraction of contacts are traced, or when there is a long delay between
218 symptom onset and isolation. This delay (D_{SM}) not only captures ineffective symptom
219 monitoring, but also the potential for symptoms to be masked for a period of time through
220 biological (e.g., natural disease progression or self-medication with anti-pyretics) or
221 behavioral (e.g., avoidance) mechanisms. In contrast, the widely-discussed “super
222 spreading” disease characteristic did not independently impact the comparative
223 effectiveness of interventions after holding the mean R_0 constant. However, this
224 characteristic could remain important to understand disease control during early, highly
225 stochastic stages of emergence¹⁷. Our findings are consistent with Fraser, Riley, et al.¹⁶
226 that both inherent transmissibility and the proportion of transmission from

227 asymptotically infected individuals are key epidemiological parameters for the
228 feasibility of control via quarantine.

229 In addition to identifying parameters that differentiate quarantine and symptom
230 monitoring, our results also characterize parameter spaces where symptom monitoring,
231 not just quarantine, is sufficient for containment of an emerging epidemic. Given the high
232 costs and poor scalability of quarantine, symptom monitoring is likely to be a key
233 intervention for future epidemic containment.

234 Although our results focus on the early stages of an outbreak, contact tracing,
235 symptom monitoring, and quarantine are often key tools for end-stage epidemic control
236 and elimination. As the effective reproductive number decreases below one (e.g. via
237 depletion of susceptible individuals, complementary interventions, seasonality, etc.), our
238 results suggest the preference for quarantine also decreases (**Fig 4**). However, one must
239 consider aspects such as geographic containment, public compliance, and, if the availability
240 of resources lags the epidemic curve, a possible resource-per-case surplus that may enable
241 the more conservative and costly approach of quarantine.

242 Our results suggest that symptom monitoring could effectively control an outbreak
243 of a new Ebola-like disease, even when infectiousness precedes symptoms and
244 interventions are not perfectly implemented. Because perfect interventions are not always
245 necessary, these results support the conclusion of Cetron et al.¹⁸ that the optimal
246 containment strategy may allow “partial or leaky quarantine” in order to increase the
247 fraction of contacts who participate.

248 The case study diseases were selected to demonstrate a broad range of natural
249 histories and are not intended to represent all candidates for quarantine and symptom

250 monitoring. Furthermore, the selected diseases have a diverse set of transmission routes,
251 including bodily fluid, fecal-oral, and airborne, which will influence the contact networks
252 and traceability of contacts. In our framework, a reduction in the fraction of contacts who
253 are ultimately traced will decrease the preference for quarantine over symptom
254 monitoring, therefore supporting the previous findings that quarantine was inefficient for a
255 respiratory disease like SARS ¹⁹.

256 We do not consider group quarantines or other non-pharmaceutical interventions
257 implemented *en masse*. For such interventions as targeting all airplane passengers
258 returning from an affected region, the time at which symptom monitoring or quarantine
259 are initiated is not necessarily linked to the timing of their infector, so does not require the
260 correlation structure of our branching model. The effectiveness and efficiency of
261 quarantine, like any intervention, improves with better targeting, hence the case for mass
262 quarantine would require additional considerations for multisectoral cost-effectiveness ⁴.
263 We propose that the most influential parameters should be prioritized for early
264 characterization during an outbreak ²⁰ and should be modeled with conservative
265 consideration of parameter uncertainty, including both real diversity and measurement
266 error. Our framework identifies the key infection-related parameters to define and can
267 form the basis of cost-benefit analyses. Such data-driven decision-making will be critical to
268 determining the optimal public health strategies for the inevitable next epidemic.

269 **METHODS**

270 **Definitions**

271 “Contact Tracing” is the process of identifying and assessing people who have been
272 exposed to a disease ³⁰. Contacts who are symptomatic when traced are immediately placed
273 in isolation; those who are not symptomatic are placed under either quarantine or
274 symptom monitoring. Here, we model “forward” contact tracing whereby an infected
275 individual names contacts they may have infected ³¹.

276 “Isolation” is the separation of a symptomatic individual believed to be infected ³⁰.
277 By reducing the number of risky contact events, isolation reduces disease transmission
278 when infectiousness coincides at least partly with symptoms.

279 “Quarantine” is the separation of an individual who is believed to be exposed, but is
280 currently not ill ³⁰. If an individual becomes symptomatic, they will be isolated and receive
281 healthcare.

282 “Symptom Monitoring” is the assessment of symptoms at regular intervals of an
283 individual believed to be exposed, but not ill. If symptoms are detected, the individual is
284 placed in isolation ³⁰. Although they may be encouraged to avoid mass-gatherings or other
285 specific events, an individual under symptom monitoring is not separated from others and
286 therefore does not experience a reduction in risky contacts until symptoms are detected.

287 “Health Seeking Behavior” is the act of seeking healthcare during the presentation of
288 symptoms, leading to isolation. Practically, this intervention could be a health education
289 campaign that prompts individuals to self-identify illness and seek effective isolation. This
290 intervention, which accelerates isolation in a manner separate from contract tracing,
291 provides a comparative care standard for our analysis.

292

293 **Model**

294 Individuals in our branching model progressed through a Susceptible-Exposed-
295 Infectious-Recovered (SEIR) disease process. We focus our analysis on the early epidemic
296 phase of an emerging infectious disease, assuming no changes to herd immunity within the
297 first few generations of transmission.

298 Following infection, the number of days before onset of infectiousness and onset of
299 symptoms are the latent period and incubation period, respectively (**Fig 1**). Because
300 clinical symptoms, pathogen concentration, and behavior of the patient can change
301 throughout the course of disease ²¹, we allowed relative infectiousness to vary with time τ
302 since onset of infectiousness (β_τ). The effective reproductive number in the presence of
303 health seeking behavior, symptom monitoring, and quarantine are respectively R_{HSB} , R_S , and
304 R_Q .

305 The recent SARS and Ebola epidemics highlighted that hospital isolation does not
306 always contain transmission, and we therefore allowed isolation effectiveness (γ) to vary to
307 reflect different settings ^{16,22,23}. The fraction of contacts who are traced (P_{CT}) can be less
308 than 1, encompassing symptomatic infectors who fail to recall contacts, asymptomatic
309 “silent” infection events, reluctance to report contacts, and challenges in identifying
310 contacts, especially for airborne transmission routes. Imperfections and uncertainties in
311 risk profiling can reduce the fraction of traced contacts that are truly infected (P_{INF}) ^{11,19}.
312 Delays in tracing a contact (D_{CT}) can arise for numerous reasons, including intractable
313 roads, low mobile phone penetration, and personnel limitations. The delay between
314 symptom onset and isolation (D_{SM}) specifically applies to individuals under symptom

315 monitoring and is influenced by the frequency of monitoring, delays in recognizing
316 sometimes unreliable clinical features, and delays in prompt isolation upon symptom
317 detection.

318

319 **Simulation**

320 We drew disease characteristics for each simulated individual from disease-specific
321 input distributions. During each hour τ of infectiousness, an individual infected a number of
322 new individuals drawn from a Poisson distribution (or, if super-spreading factor $\kappa \neq 1$, a
323 negative binomial distribution¹⁷) with mean equal to the product of the expected number
324 of onward infections for the individual (R_0) and the relative infectiousness β_τ where
325 $\sum_{\tau=1}^{d_{INF}} \beta_\tau = 1$. We assumed time-varying relative infectiousness follows a triangular
326 distribution with time of peak infectiousness (τ_β) occurring anywhere between the onset
327 and end of infectiousness, inclusively.

328 We recorded both the day of transmission and the source of each new infection for
329 each new transmission event, and drew disease characteristics for each newly infected
330 individual. An individual was identified by contact tracing with probability P_{CT} at the earlier
331 time of either when their infector is isolated or the time of the transmission event if
332 infection occurred while the infector was isolated. After an operational lag time of D_{CT} days,
333 a contact was placed under quarantine, symptom monitoring or, if already symptomatic,
334 isolation. An individual in isolation or quarantine had their infectiousness reduced by a
335 factor γ for the remainder of their disease. An individual under symptom monitoring was
336 isolated D_{SM} days after symptom onset. A full description of the model process can be found
337 in **S1 Appendix**.

338

339 **Parameterization**

340 As compared to characteristics related to the natural history of symptoms and
341 illness, key aspects of the natural history of infectiousness tend to be harder to observe and
342 measure²⁴. Therefore, we used a Sequential Monte Carlo particle filtering algorithm^{25,26} to
343 create a joint probability space of the time offset between the latent period and incubation
344 period ($T_{OFFSET} = T_{LAT} - T_{INC}$), time of peak infectiousness (τ_{β}), and duration of
345 infectiousness (d_{INF}). From an uninformative prior distribution of each parameter
346 bounded by published observations, we simulated five infection generations of 500 initial
347 individuals and recorded the simulated serial interval (i.e., the time between symptom
348 onset in infector-infectee pairs). Parameter sets were resampled with importance weights
349 determined by the degree to which the distribution of simulated serial intervals matched
350 published serial interval distributions, using the Kolmogorov-Smirnov test of the difference
351 between cumulative distribution functions (**Table S1**)^{27,28}. After perturbation, the process
352 was repeated until convergence, which we defined to be when the median Kolmogorov-
353 Smirnov statistic was within 10% of the previous two iterations. This cutoff criterion was
354 chosen to balance the objectives of finding a stationary posterior set of particles while
355 preserving some of the heterogeneity in input parameters.

356 Holding the incubation period distribution constant, we fit an offset for the latent
357 period (T_{OFFSET}) for several reasons, including consistency with CDC methods for disease
358 characterization²⁹, the biological expectation of these timings both being linked to
359 pathogen load, and to parsimoniously limit each characteristic to one interpretable
360 parameter. For the duration of infectiousness (d_{INF}), we fit the upper bound of a uniform

361 distribution with a lower bound of 1 day. To allow for variable infectiousness during this
362 duration, we assume a triangular distribution of relative infectiousness β_τ and fit the time
363 of peak infectiousness (τ_β). A full description of the model parameterization can be found
364 in the **S2 Appendix**.

365

366 **Analysis**

367 Partial rank correlation coefficients were calculated to identify the most influential
368 disease characteristics (e.g. duration of infectiousness) and intervention performance
369 metrics (e.g. isolation effectiveness). In order to remove dependence between the
370 parameters jointly fit through the particle filtering method above, we used Latin Hypercube
371 Sampling to draw 5,000 sets from each marginal posterior parameter distribution
372 independently. To maximize coverage of the parameter space we allowed fractional
373 parameters (γ , P_{CT} , P_{INF} , k) to range from 0 to 1, delays (D_{CT} , D_{SM}) to range from 0 to 7 days,
374 R_0 to range from 1 to 5, and the incubation period (T_{INC}) to be shrunk by up to 50% or
375 stretched by up to 150%.

376 Using 1,000 samples drawn from the joint-parameter space from the particle
377 filtering method, we measured R_0 , R_Q , R_S , and R_{HSB} for each disease. We compared the
378 effectiveness of symptom monitoring and quarantine by the absolute difference $R_S - R_Q$
379 and the relative difference $\frac{R_S - R_Q}{R_S}$. We calculated the number of days an infected individual
380 was in quarantine but not yet infectious (d_Q) as surrogate for the marginal cost of
381 quarantine over symptom monitoring. As surrogates for cost-effectiveness, we calculate the

382 absolute difference per quarantine day $(R_S - R_Q)/d_Q$ and relative difference per
383 quarantine day $\left(\frac{R_S - R_Q}{R_S}\right)/d_Q$ and present these results in Fig S1 and S2.

384 When risk profiling was imperfect (i.e. $P_{INF} < 1$), individuals who were not infected
385 may have been mistakenly traced as contacts and placed under symptom monitoring or
386 quarantine. Such events may be conceptualized as false positives and will decrease P_{INF} ;
387 conversely, individuals who were infected but not traced are false negatives and will
388 decrease P_{CT} . We assumed that non-infected contacts were followed for a length of time set
389 up the 95th percentile incubation period (T_{INC}^{95}), at which point health authorities may
390 conclude the contact was not infected after all. This would change the number of days in
391 quarantine to $\widehat{d}_Q = \left(d_Q + T_{inc}^{95} \left(\frac{1}{P_{inf}} - 1\right)\right)$.

392 **ACKNOWLEDGEMENTS**

393

394 CMP, LMC, and COB were supported by Cooperative Agreement U54GM088558 from the
395 National Institute Of General Medical Sciences. CMP was also supported by National
396 Research Service Award T32AI007535-16A1. YHG was supported by the National Institutes
397 of Health (K08-AI104767) and the Smith Family Foundation. The content is solely the
398 responsibility of the authors and does not necessarily represent the official views of
399 the National Institute Of General Medical Sciences or the National Institutes of Health.
400 The funders had no role in study design, data collection and analysis, decision to publish, or
401 preparation of the manuscript. The authors thank Colin Worby for helpful statistical
402 discussions.

403 **REFERENCES**

- 404
- 405 1 McMichael AJ. Environmental and social influences on emerging infectious diseases:
406 past, present and future. *Philos Trans R Soc B Biol Sci* 2004; **359**: 1049–58.
 - 407 2 Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging
408 infectious diseases. *Nature* 2004; **430**.
 - 409 3 Jones KE, Patel NG, Levy MA. Global trends in emerging infectious diseases. *Nature*
410 2008; **451**: 990–3.
 - 411 4 Barbera J, Macintyre A, Gostin L, *et al*. Large-Scale Quarantine Following Biological
412 Terrorism in the United States. *Jama* 2001; **286**: 2711–7.
 - 413 5 Union ACL, Partnership YG health J. Fear, Politics, and Ebola. How Quarantines Hurt
414 the Fight Against Ebola and Violate the Constitution. 2015
415 http://media.wix.com/ugd/148599_3c2a77dfa3c84942be9b40efacda1876.pdf.
 - 416 6 Ebola: Quarantine can undermine efforts to curb epidemic.
417 [http://www.msf.org/article/ebola-quarantine-can-undermine-efforts-curb-](http://www.msf.org/article/ebola-quarantine-can-undermine-efforts-curb-epidemic)
418 [epidemic](http://www.msf.org/article/ebola-quarantine-can-undermine-efforts-curb-epidemic).
 - 419 7 Drazen JM, Kanapathipillai R, Campion EW, *et al*. Ebola and Quarantine. *N Engl J Med*
420 2014; **371**: 2029–30.
 - 421 8 Day T, Park A, Madras N, Gumel A, Wu J. When Is Quarantine a Useful Control
422 Strategy for Emerging Infectious Diseases? *Am J Epidemiol* 2006; **163**: 479–85.
 - 423 9 Nyenswah T, Fallah M, Sieh S, *et al*. Controlling the Last Known Cluster of Ebola Virus
424 Disease — Liberia , January – February 2015. 2015; **64**: 500–4.
 - 425 10 CDC. Interim U.S. Guidance for Monitoring and Movement of Persons with Potential
426 Ebola Virus Exposure. Atlanta, Georgia, 2014
427 [http://www.cdc.gov/vhf/ebola/exposure/monitoring-and-movement-of-persons-](http://www.cdc.gov/vhf/ebola/exposure/monitoring-and-movement-of-persons-with-exposure.html)
428 [with-exposure.html](http://www.cdc.gov/vhf/ebola/exposure/monitoring-and-movement-of-persons-with-exposure.html).
 - 429 11 Chung WM, Smith JC, Weil LM, *et al*. Active Tracing and Monitoring of Contacts
430 Associated With the First Cluster of Ebola in the United States. *Ann Intern Med* 2015; :
431 1–10.
 - 432 12 Rothstein MA, Alcalde MG, Elster NR, *et al*. Quarantine and isolation: Lessons learned
433 from SARS. 2003 <http://www.iaclea.org/members/pdfs/SARS>
434 [REPORT.Rothstein.pdf](http://www.iaclea.org/members/pdfs/SARS).
 - 435 13 Gates B. The Next Epidemic — Lessons from Ebola. 2015; : 1–4.
 - 436 14 Kretzschmar M, van den Hof S, Wallinga J, van Wijngaarden J. Ring vaccination and
437 smallpox control. *Emerg Infect Dis* 2004; **10**: 832–41.
 - 438 15 Gostic KM, Kucharski AJ, Lloyd-Smith JO. Effectiveness of traveller screening for
439 emerging pathogens is shaped by epidemiology and natural history of infection. *Elife*
440 2015; **2015**: 1–16.
 - 441 16 Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious
442 disease outbreak controllable. *Proc Natl Acad Sci U S A* 2004; **101**: 6146–51.
 - 443 17 Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of
444 individual variation on disease emergence. *Nature* 2005; **438**: 355–9.
 - 445 18 Cetron M, Maloney S, Koppaka R, Simone P. Isolation and Quarantine: Containment
446 Strategies for Sars 2003. *Learn from SARS Prep Next Dis Outbreak Work Summ* 2004; :
447 71–83.
 - 448 19 Glasser JW, Hupert N, McCauley MM, Hatchett R. Modeling and public health

- 449 emergency responses: Lessons from SARS. *Epidemics* 2011; **3**: 32–7.
- 450 20 Lessler J, Edmunds WJ, Halloran ME, Hollingsworth TD, Lloyd AL. Seven challenges
451 for model-driven data collection in experimental and observational studies.
452 *Epidemics* 2015; **10**: 78–82.
- 453 21 Fine P, Eames K, Heymann DL. ‘Herd immunity’: A rough guide. *Clin Infect Dis* 2011;
454 **52**: 911–6.
- 455 22 Klinkenberg D, Fraser C, Heesterbeek H. The effectiveness of contact tracing in
456 emerging epidemics. *PLoS One* 2006; **1**: e12.
- 457 23 Lloyd-Smith JO, Galvani AP, Getz WM. Curtailing transmission of severe acute
458 respiratory syndrome within a community and its hospital. *Proc Biol Sci* 2003; **270**:
459 1979–89.
- 460 24 Richardson M, Elliman D, Maguire H, Simpson J, Nicoll A. Evidence base of incubation
461 periods, periods of infectiousness and exclusion policies for the control of
462 communicable diseases in schools and preschools. *Pediatr Infect Dis J* 2001; **20**: 380–
463 91.
- 464 25 Andrieu C, Doucet A, Singh SS, Tadic VB. Particle methods for change detection,
465 system identification, and control. *Proc IEEE* 2004; **92**: 423–38.
- 466 26 Doucet A, de Freitas N, Gordon N. An Introduction to Sequential Monte Carlo
467 Methods. *Seq Monte Carlo Methods Pract* 2001; : 3–14.
- 468 27 Djuric PM, Miguez J. Assessment of Nonlinear Dynamic Models by Kolmogorov-
469 Smirnov Statistics. *IEEE Trans Signal Process* 2010; **58**: 5069–79.
- 470 28 Marsaglia G, Tsang WW, Wang J. Evaluating Kolmogorov’s Distribution. *J Stat Softw*
471 2003; **8**: 1–4.
- 472 29 Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine
473 Preventable Diseases, 13th ed. Washington D.C.: Public Health Foundation, 2015.
- 474 30 Centers for Disease Control and Prevention. CDC Methods for Implementing and
475 Managing Contact Tracing for Ebola Virus Disease in Less-Affected Countries. 2014.
- 476 31 Muller J, Kretzschmar M, Dietz K. Contact tracing in stochastic and deterministic
477 epidemic models. *Math Biosci* 2000; **164**: 39–64.
- 478 32 Wu JT, Riley S, Fraser C, Leung GM. Reducing the Impact of the Next Influenza
479 Pandemic Using Household-Based Public Health Interventions. *PLoS Med* 2006; **3**.
480 DOI:10.1371/journal.pmed.0030361.
- 481 33 WHO Ebola Response Team. Ebola Virus Disease in West Africa - The First 9 Months
482 of the Epidemic and Forward Projections. SUPPLEMENT. *N Engl J Med* 2014;
483 published online Sept 22. DOI:10.1056/NEJMoa1411100.
- 484 34 Althaus CL. Ebola superspreading. *Lancet Infect Dis* 2015; **15**: 507–8.
- 485 35 Vink MA, Bootsma MCJ, Wallinga J. Serial Intervals of Respiratory Infectious Diseases:
486 A Systematic Review and Analysis. *Am J Epidemiol* 2014; **180**: 865–75.
- 487 36 Brodribb HS. Infective hepatitis in a boarding-school. *Lancet* 1952; : 339–42.
- 488 37 Pickles W. Epidemic Catarrhal Jaundice. *Br Med J* 1930; : 944–6.
- 489 38 Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the
490 reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic
491 review of the literature. *BMC Infect Dis* 2014; **14**: 480.
- 492 39 Viboud C, Boëlle P, Cauchemez S, *et al*. Risk factors of influenza transmission in
493 households. 2004; : 684–9.
- 494 40 Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation

495 periods of acute respiratory viral infections: a systematic review. *Lancet Infect Dis*
496 2009; **9**: 291–300.

497 41 Cauchemez S, Fraser C, Van Kerkhove MD, *et al.* Middle East respiratory syndrome
498 coronavirus: Quantification of the extent of the epidemic, surveillance biases, and
499 transmissibility. *Lancet Infect Dis* 2014; **14**: 50–6.

500 42 Assiri A, McGeer A, Perl TM, *et al.* Hospital outbreak of Middle East respiratory
501 syndrome coronavirus. *N Engl J Med* 2013; **369**: 407–16.

502 43 te Beest DE, Henderson D, van der Maas N a T, *et al.* Estimation of the serial interval
503 of pertussis in Dutch households. *Epidemics* 2014; **7**: 1–6.

504 44 Lipsitch M, Cohen T, Cooper B, *et al.* Transmission dynamics and control of severe
505 acute respiratory syndrome. *Science (80-)* 2003; **300**: 1966–70.

506 45 Nishiura H, Brockmann SO, Eichner M. Extracting key information from historical
507 data to quantify the transmission dynamics of smallpox. *Theor Biol Med Model* 2008;
508 **5**: 20.
509
510





Fig 1. Schematic of the natural history of disease and the timing of interventions.

Beginning on the left with the infection event, one progress through a latent period (T_{LAT}) before becoming infectious for d_{INF} days with late peak infectiousness τ_β . For diseases A, B, and C, symptoms are respectively shown to emerge before, concurrent with, and after onset of infectiousness. We show here an individual who is traced shortly after infection and is placed under symptom monitoring or quarantine after a short delay D_{CT} .




519

520 **Fig 2. Model dynamics and output for two exemplar diseases: Ebola and influenza A.**

521 Each line in the panels (A) and (B) designates one model run initiated with 100 infectious
522 individuals in Generation 1 and submitted to either no intervention (red), health seeking
523 behavior (teal), symptom monitoring every day (gold), or quarantine (blue) at Generation
524 3. Each point in panels C and D designates the simulated effective reproductive number
525 from one model run with input reproductive number (x-axis) between 1 and 5, with the

526 asterisk denoting the input R for panels (A) and (B) (1.83 and 1.46, respectively). Loess
527 curves are shown as heavier lines. Here, symptom monitoring performs similarly to
528 quarantine for Ebola control, but not for influenza A. Note the independent y-axes.
529




530
 531 **Fig 3. Infection control performance depends on disease biological dynamics and**
 532 **inherent transmissibility (R_0).**

533 (A) The effective reproductive number under symptom monitoring (x-axis) and quarantine
 534 (y-axis) for 100 simulations of each disease when the basic reproductive number is set to
 535 published values [See Panel C, diamonds]. Quadrants indicate regions of control with (I)
 536 neither quarantine nor symptom monitoring, (II) only symptom monitoring, (III) either
 537 quarantine or symptom monitoring, and (IV) only quarantine. (B) As in (A), but the basic
 538 reproductive number (R_0) is set to for all diseases to 2.75 (+/- 0.25) to isolate inherent
 539 differences in biological dynamics. (C) Disease-specific mean basic reproductive number
 540 (diamond) and the mean effective reproductive numbers under symptom monitoring

541 (triangle) and quarantine (circle). The length of the horizontal line therefore equals the
542 absolute comparative effectiveness $R_S - R_Q$.

543



544

545 **Fig 4. Influence of disease characteristics and intervention performance metrics.**

546 Partial rank correlation coefficients (x-axis) measuring the influence of disease


547 characteristics and intervention performance metric (rows) on the absolute (red) and

548 relative (green) comparative effectiveness of quarantine and symptom monitoring, pooled

549 for all case study diseases. The 95% confidence intervals from 100 bootstrapped samples

550 are represented by error bars.

551



552

553 **Fig 5. Minimally invasive interventions sufficient to control a hypothetical disease.**

554 (A) Disease characteristics drawn from Ebola except symptoms are assumed to either:

555 precede infectiousness by up to 10 days ($X = -10$ days); coincide with infectiousness onset

556 ($X = 0$ days); or emerge up to 10 days after infectiousness onset ($X = +10$ days). Points

557 represent simulations where health-seeking behavior (teal), symptom monitoring (gold),

558 or quarantine (blue) were the minimally sufficient intervention to bring R_e below 1. (B) As


559 in (A), but the x-axis is transformed to represent the proportion of infections that occur

560 prior to symptoms in an analogous way to Fraser, Riley, et al 2004¹⁶. Interventions are in an

561 optimal setting with all contacts being traced immediately, no infections occur during

562 isolation, and symptom monitoring is performed twice per day.

563



564

565

Fig S1. Relative comparative effectiveness and cost-effectiveness. The relative

566

comparative effectiveness varies widely by disease, with quarantine reducing R_s by >65%

567

for influenza A and hepatitis A and by <10% for pertussis. However, due to a much shorter

568


incubation period of influenza A versus hepatitis A (**Table S1**), the relative cost-

569

effectiveness measured by the reduction per day of quarantine (outlined bars) is

570

substantially higher for influenza A than hepatitis A.



571
 572 **Fig S2. Partial rank correlation coefficients for all outcomes.** Partial rank correlation
 573 coefficients (x-axis) measuring the influence of disease characteristics and intervention
 574 performance metrics (rows) on the impact, comparative effectiveness, and comparative
 575 cost-effectiveness of the interventions under study. Disease-specific estimates are shown
 576 with colored bars and pooled estimates with larger grey bars. For example, increasing the
 577 delay in tracing a named contact D_{CT} has a generally small effect negative effect on $R_S - R_Q$
 578 when pooled across diseases (large grey bar), but for influenza A specifically (purple bar),
 579 D_{CT} has a rather large negative effect on $R_S - R_Q$. Note that pooled estimates for comparative
 580 cost-effectiveness are not available due to non-monotonic relationships across diseases.
 581

582 **Table S1.** Disease parameters

	Inputs			Parameters fit via Sequential Monte-Carlo method		
	Basic Reproductive Number R_0	Serial Interval (days)	Incubation Period T_{INC} (days)	Latent period offset $T_{OFFSET} = T_{LAT} - T_{INC}$ (days)	Mean duration of infectiousness $(1 + d_{INF})/2$ (days)	Time of peak Infectiousness τ_β
Ebola	1.83 (1.72, 1.94) <small>33</small>	13.36 (2.66, 38.8) <small>34</small>	7.87 (0.93, 28.2) <small>33</small>	0.33 (0**, 1.01)	6.53 (1.28, 13.7)	0.10 (0, 0.37)
Hepatitis A	2.25 (2, 2.5) *	26.72 (20.7, 33.8) <small>35,36</small>	29.11 (24.6, 34.1) <small>37</small>	-5.33 (-7.57, -3.26)	6.23 (1.22, 15.8)	0.35 (0, 0.98)
Influenza A	1.54 (1.28, 1.80) <small>38</small>	2.20 (0.63, 3.76) <small>35,39</small>	1.40 (0.63, 3.10) <small>40</small>	-0.23 (-0.76, 0.29)	1.88 (1.04, 3.84)	0.49 (0.02, 0.98)
MERS	0.95 (0.6, 1.3) <small>41</small>	7.62 (2.48, 23.3) <small>42</small>	5.20 (1.83, 14.7) <small>42</small>	-1.55 (-3.14, 0.02)	8.35 (1.37, 19.9)	0.37 (0.01, 0.96)
Pertussis	4.75 (4.5, 5) *	19.26 (3.61, 57.2) <small>43</small>	7.00 (4.00, 10.0) <small>29</small>	-2.14 (-5.39, 0.78)	34.38 (2.67, 76.7)	0.45 (0.11, 0.88)
SARS	2.9 (2.2, 3.6) <small>44</small>	8.32 (1.59, 19.2) <small>44</small>	4.01 (1.25, 12.8) <small>40</small>	0.16 (0**, 0.67)	10.94 (1.50, 23.0)	0.10 (0, 0.46)
Smallpox	4.75 (4.5, 5) *	15.54 (9.98, 24.2) <small>45</small>	11.83 (8.47, 16.5) <small>45</small>	0.03 (-1.80, 1.68)	8.45 (1.37, 20.0)	0.32 (0, 0.97)

583 Median (95% CI)

584 * Assumed

585 ** Sequential Monte-Carlo boundary condition reached

586

587 S1 Appendix. Disease model

588 The model simulates a branching network of infected individuals only. An individual
 589 i is assigned characteristics sampled from distributions defined for each disease. The
 590 incubation period (T_{INC}), i.e. the time from infection to symptom onset, is drawn from
 591 published distributions (**Table S1**). The duration of infectiousness (d_{INF}), time of peak
 592 infectiousness (τ_β), and time offset between the latent and incubation periods (T_{OFFSET}) are
 593 drawn from the joint posterior distribution generated by the sequential Monte-Carlo (SMC)
 594 particle filtering method described in **S2 Appendix**. For clarity, we describe the method for
 595 an individual i , but the following process is repeated for an initial population of 1,000
 596 individuals who initiate distinct trees.

597 The expected number of onward infections by i , R_{0i} , is distributed over each hour τ
 598 of disease $R_{\tau i} = \beta_{\tau i} R_{0i}$, where $\beta_{\tau i}$ is the relative infectiousness of i on hour τ such that
 599 $\sum_{\tau=0}^{d_{INF}} \beta_{\tau} = 1$. For parsimony and ease of interpretation, we assume β_{τ} follows a triangle
 600 distribution with a peak value at time τ_β drawn from the SMC posterior.

$$\beta_{\tau i} = \begin{cases} \sqrt{\tilde{u} d_{INF} \tau_\beta} & , \text{ if } \tilde{u} < \tau_\beta / d_{INF} \\ d_{INF} - \sqrt{(1 - \tilde{u})(d_{INF} - \tau_\beta)(d_{INF})} & , \text{ otherwise} \end{cases}$$

601 where $\tilde{u} \sim \text{unif}(0,1)$

602 The number of infections ($N_{\tau i}$) generated by individual i at hour τ is drawn from a
 603 negative binomial distribution with mean equal to $R_{\tau i}$ and dispersion factor κ to capture
 604 super spreading tendencies. If $\kappa = 1$, the negative binomial distribution reduces to a
 605 Poisson distribution with rate $\lambda = R_{\tau i}$.

606 Each individual i then has a vector of $\langle N_{0i}, N_{1i}, \dots, N_{d_{inf}i} \rangle$ of onward infections that
 607 occur during each hour $\tau \in \langle 0, 1, \dots, d_{INF} \rangle$. A new individual j is generated for each onward
 608 infection $N_{\tau i} \geq 1$. Disease characteristics for j are drawn as above, adding the time of
 609 infection to the latent and incubation periods for j .

610 Contact j of infector i will be traced with probability P_{CT} . If traced, j is placed under
 611 symptom monitoring or quarantine with an operational lag time of D_{CT} days. The lag time
 612 occurs after the earlier of isolation or removal from the disease system upon recovery or
 613 death for individual i . We assume individuals granted access to the quarantine or isolation
 614 room will be logged and given the same attention as contacts traced through
 615 epidemiological interview and will therefore will begin monitoring or quarantine at the
 616 time of the infection control breach or transmission event.

617 Next we determine the time of isolation for j . If time of symptom onset for j occurs
 618 before j is traced, j is immediately isolated (**Panel 1**). Otherwise, time of isolation for j
 619 depends on whether symptom monitoring or quarantine is used. Under symptom
 620 monitoring, isolation of j occurs a delay D_{SM} days after symptom onset. Note that for
 621 contacts checked twice-daily, $D_{SM} \sim \text{unif}(0, 0.5)$. Upon isolation, the hourly expected number
 622 of onward infections is reduced to $R_{t_j} = (1 - \gamma)\beta_{t_j} R_{0j}$ where γ is effectiveness of isolation
 623 with support $[0, 1]$. If j is under quarantine, then R_{t_j} is reduced by $(1 - \gamma)$ beginning at the
 624 time j is traced.

625 S2 Appendix. Parameterization via Sequential Monte Carlo

626

627 The following parameterization method was repeated for each case study disease.
628 Data-informed incubation period and serial interval distributions were collected through a
629 literature review. Sequential Monte-Carlo (also known as particle filtering) methods were
630 used to estimate the joint distribution of three disease parameters (T_{OFFSET} , d_{INF} , and τ_{β})
631 using knowledge of the incubation period and serial interval distributions [28,29].

632 Here we assume that the latent period for an individual is some time (T_{OFFSET})
633 before ($T_{OFFSET} < 0$) or after ($T_{OFFSET} > 0$) the onset of symptoms. Therefore, T_{OFFSET} is a
634 translation of the incubation period distribution. We assume a uniform distribution of
635 duration of infectiousness from 1 day to d_{INF} , allowing for partial days as well. We assume
636 the distribution of relative infectiousness to follow a triangle distribution with a max at
637 time τ_{β} , which ranges from 0, indicating infectiousness is linearly decreasing, to 1,
638 indicating infectiousness is linearly increasing.

639 The steps are as follows:

640

- 641 i. Draw initial parameter set Θ consisting of T_{OFFSET} , d_{INF} , and τ_{β} from a
642 Latin Hypercube sample bounded by the range of parameter values
643 found in the literature (Note: d_{INF} is loosely bounded by symptom
644 observations).
- 645 ii. Run the branching epidemic model under a situation with no
646 interventions and measure the simulated serial intervals.
- 647 iii. Compare the simulated serial intervals to the published serial
648 interval(s) in the literature using the Kolmogorov-Smirnov test statistic
649 (KS).
- 650 iv. Draw a bootstrapped sample of $\Theta_{candidate}$ from Θ weighted by the KS
651 statistic and restricted by an adaptive Θ threshold of (max KS in
652 trial)*0.80
- 653 v. Perturb each $\Theta_{candidate}$ by up to 2% of the initial parameter value range
- 654 vi. Repeat steps (ii)-(v) until the median KS is within 10% of each of the
655 previous two rounds.
- 656 vii. Generate an unweighted sample from final Θ joint probability space
657 with replacement as the input parameter set for the case studies.
- 658 viii. To calculate partial rank correlation coefficients generate an
659 unweighted sample with replacement from the parameter space of each
660 of for T_{OFFSET} , d_{INF} , and τ_{β} independent distributions from Θ .

661

662